1 result for "WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD."
Add this URL to any RSS reader. Updated daily.
Polymers for Hyperuricemia Treatment Granted to Waterstone
The USPTO granted patent US12605401B2 to Waterstone Pharmaceuticals (Wuhan) Co., Ltd. covering polymers and compositions for binding uric acid and treating hyperuricemia, gout, and related diseases. The patent, with 20 claims, was filed on May 18, 2022 under Application No. 17747006 and lists eight inventors.
Routine
Notice
Intellectual Property
Get alerts for "WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD."
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Browse Categories
Agriculture & Food Safety
73
AI Regulation
3
Banking & Finance
412
Consumer Protection
89
Courts & Legal
411
Data Privacy & Cybersecurity
90
Defense & National Security
53
Education
55
Energy
100
Environment
152
Gaming
2
Government & Legislation
430
Healthcare
15
Healthcare & Life Sciences
375
Immigration
10
Insurance
76
Labor & Employment
134
Pharma & Drug Safety
21
Professional Licensing
8
Real Estate & Housing
78
Securities & Markets
154
Tax
78
Telecom & Technology
47
Trade & Sanctions
141
Transportation
91
Get alerts for "WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD."
We'll email you when new changes match "WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD.".
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.
You're subscribed!